Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Abstract | PURPOSE: DESIGN: Additional follow-up of a randomized trial cohort. PARTICIPANTS: METHODS: MAIN OUTCOME MEASURES: Local and systemic potential complications of the therapies and self-reported health utility and vision-related and generic health-related QoL were studied prospectively. RESULTS: Among initially phakic eyes, cataract and cataract surgery occurred significantly more often in the implant group (hazard ratio [HR], 3.0; P = 0.0001; and HR, 3.8; P < 0.0001, respectively). In the implant group, most cataract surgery occurred within the first 2 years. Intraocular pressure elevation measures occurred more frequently in the implant group (HR range, 3.7-5.6; all P < 0.0001), and glaucoma (assessed annually) also occurred more frequently (26.3% vs. 10.2% by 48 months; HR, 3.0; P = 0.0002). In contrast, potential complications of systemic therapy, including measures of hypertension, hyperlipidemia, diabetes, bone disease, and hematologic and serum chemistry indicators of immunosuppression toxicity, did not differ between groups through 54 months. Indices of QoL initially favored implant therapy by a modest margin. However, all summary measures of health utility and vision-related or generic health-related QoL were minimally and nonsignificantly different by 54 months, with the exception of the 36-item Short-Form Health Survey physical component summary score, which favored implant by a small margin at 54 months (3.17 on a scale of 100; P = 0.01, not adjusted for multiple comparisons). Mean QoL results were favorable in both groups. CONCLUSIONS: These results suggest that fluocinolone acetonide implant therapy is associated with a clinically important increased risk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and early intervention to prevent glaucoma is warranted with implant therapy. Systemic therapy subjects avoided a significant excess of toxicities of systemic corticosteroid and immunosuppressive therapies in the trial. Self-reported QoL measures initially favored implant therapy, but over time the measures converged, with generally favorable QoL in both groups.
|
Authors | Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group |
Journal | Ophthalmology
(Ophthalmology)
Vol. 122
Issue 10
Pg. 1976-86
(Oct 2015)
ISSN: 1549-4713 [Electronic] United States |
PMID | 26298718
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 American Academy of Ophthalmology. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Drug Implants
- Glucocorticoids
- Fluocinolone Acetonide
- Prednisone
|
Topics |
- Adult
- Aged
- Anti-Inflammatory Agents
(administration & dosage, adverse effects)
- Cataract
(chemically induced)
- Drug Implants
- Female
- Fluocinolone Acetonide
(administration & dosage, adverse effects)
- Follow-Up Studies
- Glaucoma
(chemically induced)
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Intraocular Pressure
(drug effects)
- Male
- Middle Aged
- Panuveitis
(drug therapy, physiopathology, psychology)
- Prednisone
(administration & dosage, adverse effects)
- Prospective Studies
- Quality of Life
(psychology)
- Risk Factors
- Uveitis, Intermediate
(drug therapy, physiopathology, psychology)
- Uveitis, Posterior
(drug therapy, physiopathology, psychology)
- Visual Acuity
(drug effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|